Initiating: Turning Point Therapeutics

San Diego based Turning Point Therapeutics is an oncology focused biotech that completed a successful IPO in April this year, raising about $190M with pricing at $18/sh. As the stock.

ARQL- Quick Take

I have been following Arqule off and on for quite some time. The company has been reborn after so many lost years pursuing its failed MET inhibitor ARQ 197. Hopes.

Zogenix Acquires Modis Therapeutics

Aug 27, 2019 by Jason Chew Zogenix announced yesterday that it is acquiring privately held Modis Therapeutics. It gains access to the late stage substrate enhancement therapy, MT1621, for the.

Coverage Continuation- ARVN

Aug 23, by Jason Chew Arvinas is one of the newer names I’ve been covering. The company is developing a new class of drugs with a new modality known as.

Coverage Continuation- ZGNX

Aug 19, 2019 by Jason Chew Zogenix ran into some unwelcome surprise this April when FDA kicked back its ZX008 (Fintepla) NDA with a Refuse to File letter. The two deficiencies cited.

Coverage Continuation – ZYME

Aug 14, 2019 by Jason Chew Zymeworks is perhaps one of my favorite stocks. The small/mid cap Canadian biotech has expertise in bispecific antibody technology. Bispecifics are an exploding field,.

Coverage Continuation: SAGE

It has been a long time since my last article, but with the forum down, there is a lot to catch up on. My coverage will focus on the eight.

August 12th Biotech Update

Another week with another set of macro concerns. I was waiting to see if there would be any interesting biotech news but I guess not. There was some late last.

DMD Data by Giant Pharma Pfizer Kept Sarepta In the Driver Seat with Superior Drug

Pfizer (PFE) presented its first set of data (n=6) from the mini-dystrophin gene therapy for DMD (PF-06939926) at the PPMD conference on June 28th. Much speculations surrounded Pfizer’s decision to.

June 25 Biotech Update

So that was unexpected. First, the market is down and sector is higher. Second, we got another large merger to digest. Obviously I will focus on the deal and its.

May 6th Biotech Update

Not the best start to the week for the market with the surprise tariff news hitting the market. I would not be stunned for the effect to be muted given.

Sarepta – LGMD2E Data May Become the Next Inflection Point

Sarepta Therapeutics (SRPT) has a long history with several inflection points through the years. Moving upward from a penny stock back in the days they used to be called AVI.

PSTI – The Future Regenerative Medicine Leader – Trading Under the Radar

• Regenerative medicine company with late-stage studies in 3 indications • Ready to use GMP-certified manufacturing facility for PLX cells • Aging is often associated with debilitating medical conditions, massive.

Bria-IMT Combination Study with KEYTRUDA®: What the Early Data Show

BriaCell presented some data from the ongoing Phase IIa combination clinical trial of Bria-IMT™ with Merck’s (NYSE: MRK) KEYTRUDA® [(pembrolizumab)], as listed in ClinicalTrials.gov as NCT03328026, in advanced breast cancer.

CEO Interview: Bellus Outlook Post the Positive Ph1 Chronic Cough Study

Back in August I published my deep dive report “Bellus – David vs. Goliath, Can BLU Deliver A Better Chronic Cough Drug Than Merck?” (Link) with a bull thesis stating.

Dave-Trading November 2018

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

Bria-IMT Combination Study with KEYTRUDA®: What to Know and Why

In a previous interview, BriaCell (TSX:BCT.V) (OTCQB:BCTXF) (or the Company)’s President and CEO, Dr. Bill Williams cited as a near-term catalyst data from the Company’s ongoing Phase IIa combination clinical.

Opinion: No, The Antibiotics Market Is Not Broken

In light of slow drug launches and disappointing sales, there is a growing chorus of voices saying the antibiotics drug market is broken; that the government must step in to.

Bellus – David vs. Goliath Round 2 – Can BLU Expand the Pipeline Following Merck Lead?

Back in August I published my first deep dive report “Bellus – David vs. Goliath Can BLU Deliver A Better Chronic Cough Drug Than Merck?” (Link) about Bellus Health (BLU.TO).

APTO – We Came for A Trade and Back for The Long-Term Potential

The First time I met Aptose Biosciences (APTO) was at the Bloom-Burton conference in Toronto back in May 2018 following the request of several Chimera Research Group (CRG) subscribers. They.

Browsing 20 / 467 articles